NCT00089830View on ClinicalTrials.gov

"A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat Wet Age-Related Macular Degeneration"

PHASE2TerminatedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

May 31, 2007

Conditions
Macular Degeneration
Interventions
DRUG

MSI-1256F (Squalamine Lactate)

Trial Locations (1)

19462

Genaera Corporation, Plymouth Meeting

Sponsors
All Listed Sponsors
lead

Genaera Corporation

INDUSTRY